38692-80-7

Basic information

• Product Name: 3-BROMO-4-HYDROXYPHENYLACETIC ACID
• Synonyms: 3-BROMO-4-HYDROXYBENZENEACETIC ACID;3-BROMO-4-HYDROXYPHENYLACETIC ACID;3-Bromo-4-hydroxyphenyl;2-(3-bromo-4-hydroxyphenyl)acetic acid
• CAS NO: 38692-80-7
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• EINECS: 254-089-8
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Organic acids
• Mol File: 38692-80-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 105-107℃
• Boiling Point: 364℃
• Flash Point: 174℃
• Appearance: /
• Density: 1.757
• Vapor Pressure: 6.18E-06mmHg at 25°C
• Refractive Index: 1.632
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.33±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(38692-80-7)
• EPA Substance Registry System: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(38692-80-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 38692-80-7(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-hydroxyphenylacetic acid is a chemical compound with the molecular formula C8H7BrO3. It belongs to the class of phenylacetic acids, which are organic compounds commonly used in the synthesis of pharmaceuticals. 3-Bromo-4-hydroxyphenylacetic acid is a derivative of phenylacetic acid and contains a bromine atom and a hydroxy group attached to a benzene ring. It is used as a building block in the chemical synthesis of various pharmaceuticals and is often employed in medicinal chemistry research. The compound has potential applications in the development of drugs for various therapeutic purposes.

InChI:InChI=1/C8H7BrO3/c9-6-3-5(4-8(11)12)1-2-7(6)10/h1-3,10H,4H2,(H,11,12)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 74270-54-5 4-hydroxy-3-bromomandelic acid 
• 95-56-7 2-hydroxybromobenzene 
• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 

Downstream Products

• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 29121-25-3 ethyl 2-(3-bromo-4-hydroxyphenyl)acetate 
• 124840-59-1 4-Benzyloxy-3-brom-phenylessigsaeure-benzylester 
• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 5884-61-7 (4-hydroxy-3,4'-oxy-diphenyl)-di-acetic acid 
• 42583-41-5 2-{4-[5-(carboxymethyl)-2-methoxyphenoxy]phenyl}acetic acid 
• 655237-87-9 1-(3-bromo-4-hydroxyphenyl)-acetone 
• 303012-68-2 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone 
• 1201916-20-2 C₁₈H₁₇BrN₂O₂ 
• 1201916-22-4 C₁₈H₁₆Br₂N₂O₂ 
• 1258845-78-1 3-[2-(3-bromo-4-hydroxyphenyl)acetamido]-2-(4-tertbutylbenzyl)propyl pivalate 
• 1254646-35-9 2-[4-hydroxy-3-pentylphenyl]acetic acid 
• 1391574-01-8 benzyl (E)-2-[4-benzyloxy-3-[pent-1-enyl]phenyl]acetate 

Relevant articles and documents

Novel total synthesis method of racemic tetrandrine

The invention discloses a novel total synthesis method of racemic tetrandrine, and belongs to the technical field of pharmaceutical chemical synthesis. 5-bromovanillin and 4-hydroxyphenylacetic acid which are low in price and easy to obtain are respectively used as starting materials to synthesize a compound 10, the compound 10 is used for synthesizing a compound 12 and a compound 14 through a simple route, and the two compounds are subjected to intermolecular and intramolecular Ullmann reaction to synthesize the racemic tetrandrine A. The key intermediates 12 and 14 are synthesized through the compound 10, the synthesis efficiency is greatly improved, the raw materials are utilized to the maximum extent, and the method is a racemic tetrandrine total synthesis route which is simplest in operation and lowest in cost so far.

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.